Pulmonology

Vaccine uptake this respiratory virus season is lagging compared to previous years, says Schaffner, medical director of the National Foundation for Infectious Diseases.

Check your knowledge of mechanistic features of severe asthma, specific biomarker level cut offs, and impact of comorbid disease on choice of biologic treatment.

The approval offers patients the choice to administer the monoclonal antibody at home using a prefilled device or to continue to receive it in a clinical setting.

COPD was associated with a 61% increase in risk of death and 13% greater total costs in the year after surgery, according to a new study.

Severe uncontrolled asthma is a clinical treatment challenge even with advanced biologic therapies available. Test your knowledge of a few key characteristics with a quick quiz.

Distinguishing between influenza, COVID-19, and RSV and persuading vaccine-weary patients to get vaccinated are some of the challenges this season, says William Schaffner, MD.

Asthma exacerbations in children living in low-income urban areas were significantly associated with reduced air quality and specific pollutants in a new analysis.

The mRNA vaccine returned efficacy of 83.7% against RSV-associated lower respiratory tract disease defined by ≥2 symptoms and of 82.4% against disease defined by ≥3 symptoms.

Exacerbation history alone is unlikely to provide clinical utility for predicting future COPD exacerbations and could be associated with a risk of harm, according to new analysis.

If approved, nirsevimab would be the first single-dose RSV preventative option for the broad newborn and infant population in the US.

Adherence to several different healthy eating patterns was associated with reduced risk for all- and specific-cause mortality in a large prospective cohort study with 36 years of follow-up.

Among the CDC vaccine advisory group's recommendations are adding COVID-19 vaccines to the Vaccine for Children program and allowing PCV20 shots for those who previously received PCV13.

The FDA has granted priority review to a biologics license application for Pfizer’s respiratory syncytial virus vaccine candidate, RSVpreF, for adults aged ≥60 years.

Your daily dose of clinical news you may have missed.

The inpatient flu census doubled after Thanksgiving travel and gatherings and ICU beds are full. More at-a-glance stats on Flu in the USA, here.

Flu rates are up after the Thanksgiving holiday week, COVID-19 hospitalizations are increasing, and RSV may or may not be on the wane as Christmas approaches.

Respiratory syncytial virus is an age-old winter foe that could affect many of your patients this year. Take a minute and scan these facts for a refresher.

RSV is back for the 2022-23 respiratory virus season and is unfamiliar to many. Click through this quick collection of myths already in circulation to prepare.

The FDA accepted the GSK BLA and granted priority review to what could be the first vaccine approved against RSV in adults aged ≥60 years, according to the company.

Topline phase 3 trial data showed 81.8% efficacy for the maternal vaccine against severe RSV-related illness in infants from birth through first 90 days of life.

The GSK RSV vaccine candidate has received favorable international regulatory attention which may be an auspicious sign for the US.

Your daily dose of clinical news you may have missed.

IDWeek 2022: New data show a greater than 60% reduction in acute exacerbations and need for antibiotics in patients with CS who used fluticasone propionate nasal spray.

The high-dose influenza vaccines provided greater relative vaccine effectiveness/efficacy vs standard dose in a cohort of more than 45 million.